Today is shaping up negative for Voyager Therapeutics, Inc. (NASDAQ:VYGR) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

After the downgrade, the consensus from Voyager Therapeutics' ten analysts is for revenues of US$21m in 2026, which would reflect a sizeable 40% decline in sales compared to the last year of performance. The loss per share is expected to ameliorate slightly, reducing to US$1.68. However, before this estimates update, the consensus had been expecting revenues of US$39m and US$1.61 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

Of course, another way to look at these forecasts is to place them into context against the industry itself. Over the past five years, revenues have declined around 4.5% annually. Worse, forecasts are essentially predicting the decline to accelerate, with the estimate for an annualised 64% decline in revenue until the end of 2026. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 23% per year. So while a broad number of companies are forecast to grow, unfortunately Voyager Therapeutics is expected to see its sales affected worse than other companies in the industry.

The Bottom Line

The most important thing to take away is that analysts increased their loss per share estimates for this year. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on Voyager Therapeutics after today.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Voyager Therapeutics going out to 2028, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.